Regulus Therapeutics Inc (RGLS)
2.70
+0.20
(+8.00%)
USD |
NASDAQ |
May 02, 15:56
Regulus Therapeutics Research and Development Expense (Quarterly): 5.763M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.763M |
| September 30, 2023 | 5.488M |
| June 30, 2023 | 4.976M |
| March 31, 2023 | 4.925M |
| December 31, 2022 | 4.713M |
| September 30, 2022 | 5.31M |
| June 30, 2022 | 4.708M |
| March 31, 2022 | 3.679M |
| December 31, 2021 | 4.409M |
| September 30, 2021 | 5.915M |
| June 30, 2021 | 4.15M |
| March 31, 2021 | 3.32M |
| December 31, 2020 | 3.951M |
| September 30, 2020 | 4.036M |
| June 30, 2020 | 4.242M |
| March 31, 2020 | 3.119M |
| December 31, 2019 | 2.09M |
| September 30, 2019 | 2.44M |
| June 30, 2019 | 1.836M |
| March 31, 2019 | 5.983M |
| December 31, 2018 | 5.255M |
| September 30, 2018 | 6.879M |
| June 30, 2018 | 10.01M |
| March 31, 2018 | 11.83M |
| December 31, 2017 | 10.46M |
| Date | Value |
|---|---|
| September 30, 2017 | 12.70M |
| June 30, 2017 | 14.28M |
| March 31, 2017 | 15.75M |
| December 31, 2016 | 14.98M |
| September 30, 2016 | 14.55M |
| June 30, 2016 | 18.01M |
| March 31, 2016 | 16.76M |
| December 31, 2015 | 12.79M |
| September 30, 2015 | 10.96M |
| June 30, 2015 | 19.20M |
| March 31, 2015 | 13.43M |
| December 31, 2014 | 10.47M |
| September 30, 2014 | 10.17M |
| June 30, 2014 | 10.80M |
| March 31, 2014 | 9.604M |
| December 31, 2013 | 8.232M |
| September 30, 2013 | 7.106M |
| June 30, 2013 | 7.722M |
| March 31, 2013 | 6.883M |
| December 31, 2012 | 5.607M |
| September 30, 2012 | 5.248M |
| June 30, 2012 | 4.883M |
| March 31, 2012 | 4.603M |
| December 31, 2011 | 4.466M |
| September 30, 2011 | 3.875M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.836M
Minimum
Jun 2019
5.915M
Maximum
Sep 2021
4.162M
Average
4.242M
Median
Jun 2020
Research and Development Expense (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | 66.74M |
| ADMA Biologics Inc | 0.4455M |
| FibroGen Inc | 51.70M |
| Protara Therapeutics Inc | 6.381M |
| Amylyx Pharmaceuticals Inc | 44.91M |